Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:acquiredBy |
gptkb:Ortho_Clinical_Diagnostics
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:CEO |
gptkb:Douglas_Bryant
|
| gptkbp:founded |
1979
|
| gptkbp:founder |
gptkb:Shelley_H._Boyce
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Quidel Corporation
|
| gptkbp:industry |
medical diagnostics
|
| gptkbp:ISIN |
US74838J1016
|
| gptkbp:notableProduct |
gptkb:QuickVue_At-Home_COVID-19_Test
gptkb:Sofia_SARS_Antigen_FIA |
| gptkbp:numberOfEmployees |
approximately 1,200 (2022)
|
| gptkbp:products |
immunoassays
rapid diagnostic tests molecular diagnostic tests diagnostic healthcare products |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:revenue |
$1.7 billion (2021)
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:QDEL
|
| gptkbp:website |
https://www.quidel.com/
|
| gptkbp:bfsParent |
gptkb:Ortho-Clinical_Diagnostics
gptkb:Ortho_Clinical_Diagnostics |
| gptkbp:bfsLayer |
7
|